poisar

Stocks · News reference

UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $627

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Mexico Animal Healthcare Market Size and Share Analysis - Industry Trends and Growth Forecasts (2026-2031) | Diagnostics and Pet Care Fuel Growth to USD 3.34 Billion

    Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.

  2. The Motley FoolDavid Kretzmann

    IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction

    IDEXX Laboratories reported Q3 2026 revenue growth of 10% to $1.21 billion, driven by 11% growth in recurring diagnostics sales. While the company raised its 2026 earnings forecast and shares surged 16%, the profit increase stems from tax benefits, lower interest costs, and buybacks rather than testing demand. Notably, IDEXX trimmed its operating margin outlook, with Q4 expected to show minimal margin improvement as the company absorbs costs from its CoVet software acquisition.